Zogenix Gets US Patent For ZX008 in Dravet Syndrome

Zogenix shares were up pre-market Monday after the company said it was issued a U.S. patent for ZX008 for the treatment of Dravet Syndrome from the U.S. Patent & Trademark Office.

“We are continuing to pursue multiple additional patent families related to ZX008 globally in order to further protect our lead product candidate,” CEO Stephen Farr said. “In addition, we are conducting certain pre-clinical and clinical development work in order to leverage additional potential intellectual property opportunities.”

ZX008 is designated as an orphan drug in both the U.S. and Europe, and also received fast track designation in the U.S., for the treatment of Dravet syndrome.

Leave a Comment